Page 95 - Read Online

Page 10 of 12 Solimando et al. J Cancer Metastasis Treat 2022;8:9 https://dx.doi.org/10.20517/2394-4722.2021.166

11. Vleeming W, van Rooij HH, Wemer J, Porsius AJ. Cardiovascular responses to the stereoisomers of dobutamine in isolated rat hearts
48 hours after acute myocardial infarction. J Cardiovasc Pharmacol 1991;17:634-40. DOI PubMed
12. Ambrosi TH, Scialdone A, Graja A, et al. Adipocyte accumulation in the bone marrow during obesity and aging impairs stem cell-
based hematopoietic and bone regeneration. Cell Stem Cell 2017;20:771-84.e6. DOI PubMed PMC
13. Pietras EM. Inflammation: a key regulator of hematopoietic stem cell fate in health and disease. Blood 2017;130:1693-8. DOI
PubMed PMC
14. Reynaud D, Pietras E, Barry-Holson K, et al. IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic
myelogenous leukemia development. Cancer Cell 2011;20:661-73. DOI PubMed PMC
15. Gondek LP. CHIP: is clonal hematopoiesis a surrogate for aging and other disease? Hematology Am Soc Hematol Educ Program
2021;2021:384-9. DOI PubMed PMC
16. Tomasetti C, Vogelstein B. Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell
divisions. Science 2015;347:78-81. DOI PubMed PMC
17. Jaiswal S, Ebert BL. Clonal hematopoiesis in human aging and disease. Science 2019;366:eaan4673. DOI PubMed PMC
18. Young AL, Challen GA, Birmann BM, Druley TE. Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in
healthy adults. Nat Commun 2016;7:12484. DOI PubMed PMC
19. Zink F, Stacey SN, Norddahl GL, et al. Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly.
Blood 2017;130:742-52. DOI PubMed PMC
20. Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl
J Med 2014;371:2477-87. DOI PubMed PMC
21. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med
2014;371:2488-98. DOI PubMed PMC
22. Coombs CC, Zehir A, Devlin SM, et al. Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common
and associated with adverse clinical outcomes. Cell Stem Cell 2017;21:374-382.e4. DOI PubMed PMC
23. Gnoni A, Brunetti O, Longo V, et al. Immune system and bone microenvironment: rationale for targeted cancer therapies. Oncotarget
2020;11:480-7. DOI PubMed PMC
24. Elias HK, Bryder D, Park CY. Molecular mechanisms underlying lineage bias in aging hematopoiesis. Semin Hematol 2017;54:4-11.
DOI PubMed
25. Watson CJ, Papula AL, Poon GYP, et al. The evolutionary dynamics and fitness landscape of clonal hematopoiesis. Science
2020;367:1449-54. DOI PubMed
26. Gibson CJ, Kim HT, Zhao L, et al. Donor clonal hematopoiesis and recipient outcomes after transplantation. J Clin Oncol
2022;40:189-201. DOI PubMed PMC
27. Bolton KL, Ptashkin RN, Gao T, et al. Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat Genet 2020;52:1219-
26. DOI PubMed PMC
28. Wong TN, Ramsingh G, Young AL, et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid
leukaemia. Nature 2015;518:552-5. DOI PubMed PMC
29. McNerney ME, Godley LA, Le Beau MM. Therapy-related myeloid neoplasms: when genetics and environment collide. Nat Rev
Cancer 2017;17:513-27. DOI PubMed PMC
30. Yoshizato T, Dumitriu B, Hosokawa K, et al. Somatic mutations and clonal hematopoiesis in aplastic anemia. N Engl J Med
2015;373:35-47. DOI PubMed PMC
31. Sun L, Babushok DV. Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal
hemoglobinuria. Blood 2020;136:36-49. DOI PubMed PMC
32. Jaiswal S, Libby P. Clonal haematopoiesis: connecting ageing and inflammation in cardiovascular disease. Nat Rev Cardiol
2020;17:137-44. DOI PubMed
33. Jaiswal S, Natarajan P, Silver AJ, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med
2017;377:111-21. DOI PubMed PMC
34. Fuster JJ, MacLauchlan S, Zuriaga MA, et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis
development in mice. Science 2017;355:842-7. DOI PubMed PMC
35. Wolach O, Sellar RS, Martinod K, et al. Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative
neoplasms. Sci Transl Med 2018;10:eaan8292. DOI PubMed PMC
36. Furman D, Campisi J, Verdin E, et al. Chronic inflammation in the etiology of disease across the life span. Nat Med 2019;25:1822-32.
DOI PubMed PMC
37. Fraenkel PG. Anemia of inflammation: a review. Med Clin North Am 2017;101:285-96. DOI PubMed PMC
38. Bruin AM, Voermans C, Nolte MA. Impact of interferon-γ on hematopoiesis. Blood 2014;124:2479-86. DOI PubMed
39. Zamai L, Secchiero P, Pierpaoli S, et al. TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human
erythropoiesis. Blood 2000;95:3716-24. PubMed
40. Baldridge MT, King KY, Boles NC, Weksberg DC, Goodell MA. Quiescent haematopoietic stem cells are activated by IFN-gamma in
response to chronic infection. Nature 2010;465:793-7. DOI PubMed PMC
41. Essers MA, Offner S, Blanco-Bose WE, et al. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature 2009;458:904-8.
DOI PubMed
42. Esplin BL, Shimazu T, Welner RS, et al. Chronic exposure to a TLR ligand injures hematopoietic stem cells. J Immunol
2011;186:5367-75. DOI PubMed PMC